Advances in translational research in breast cancer; a bridge to future therapies

European Journal of Cancer

Volumn 44, Issue 18, 2008, Pages 2705-2706

  Sotiriou, Christos ^a   Pusztai, Lajos ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA;

ANGIOGENESIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; DNA POLYMORPHISM; EDITORIAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HYPOXIA; MASS SPECTROMETRY; METASTASIS; MICROENVIRONMENT; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEOMICS; RNA TRANSLATION; STEM CELL; TUMOR BIOPSY; TUMOR CELL; TUMOR GROWTH;

BIOMEDICAL RESEARCH; BREAST NEOPLASMS; FEMALE; GENETIC TECHNIQUES; HUMANS;

EID: 56949094536     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.10.007     Document Type: Editorial

References (20)

1. Conrad D.F., Andrews T.D., Carter N.P., Hurles M.E., and Pritchard J.K. A high-resolution survey of deletion polymorphism in the human genome. Nature Genetics 38 (2006) 75-81
2. Little D.P., Braun A., O'Donnell M.J., and Koester H. Mass spectrometry from miniaturized arrays for full comparative DNA analysis. Nat Med 3 (1997) 1413-1416
3. Henikoff S. ENCODE and our very busy genome. Nature Genetics 39 (2007) 817-818
4. Wood L.D., Parsons D.W., Jones S., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 5853 (2007) 1108-1113
5. Aderem A. Systems biology: its practice and challenges. Cell 121 4 (2005) 511-513
6. Loi S. Molecular analysis of hormone receptor positive (luminal) breast cancers - What have we learnt?. Eur J Cancer 44 (2008) 2813-2818 10.1016/j.ejca.2008.09.012
7. Irvin Jr. W.J., and Carey L.A. What is triple-negative breast cancer?. Eur J Cancer 44 (2008) 2799-2805 10.1016/j.ejca.2008.09.034
8. Desmedt C., Ruíz-García E., and Adré F. Gene expression predictors in breast cancer: Current status, limitations and perspectives. Eur J Cancer 44 (2008) 2714-2720 10.1016/j.ejca.2008.09.011
9. Tutt A., and Ashworth A. Can genetic testing guide treatment in breast cancer?. Eur J Cancer 44 (2008) 2774-2780 10.1016/j.ejca.2008.10.009
10. Latterich M., Abramovitz M., and Leyland-Jones B. Proteomics: New technologies and clinical applications. Eur J Cancer 44 (2008) 2737-2741 10.1016/j.ejca.2008.09.007
11. Iorio M.V., Casalini P., Tagliabue E., Ménard S., and Croce C.M. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer 44 (2008) 2753-2759 10.1016/j.ejca.2008.09.037
12. Simon R. Lost in translation: Problems and pitfalls in translating laboratory observations to clinical utility. Eur J Cancer 44 (2008) 2707-2713 10.1016/j.ejca.2008.09.009
13. Di Leo A., Biganzoli L., Clandino W., Licitra S., Pestrin M., and Larsimont D. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: Ready for the primetime?. Eur J Cancer 44 (2008) 2791-2798 10.1016/j.ejca.2008.09.014
14. Milani M., and Harris A.L. Targeting tumour hypoxia in breast cancer. Eur J Cancer 44 (2008) 2766-2773 10.1016/j.ejca.2008.09.025
15. Hu M., and Polyak K. Molecular characterization of the tumour microenvironment in breast cancer. Eur J Cancer 44 (2008) 2760-2765 10.1016/j.ejca.2008.09.038
16. Klein C.A. The direct molecular analysis of metastatic precursor cells in breast cancer: A chance for a better understanding of metastasis and for personalised medicine. Eur J Cancer 44 (2008) 2721-2725 10.1016/j.ejca.2008.09.035
17. Ignatiadis M., Georgoulias V., and Mavroudis D. Micrometastatic disease in breast cancer: Clinical implications. Eur J Cancer 44 (2008) 2726-2736 10.1016/j.ejca.2008.09.033
18. Di Cosimo S., and Baselga J. Targeted therapies in breast cancer: where are we now?. Eur J Cancer 44 (2008) 2781-2790 10.1016/j.ejca.2008.09.026
19. Dean-Colomb W., and Esteva F.J. HER2-positive breast cancer: Herceptin and beyond. Eur J Cancer 44 (2008) 2806-2812 10.1016/j.ejca.2008.09.013
20. Zakhireh J., Gomez R., and Esserman L. Converting evidence to practice: A guide for the clinical application of MRI for the screening and management of breast cancer. Eur J Cancer 44 (2008) 2742-2752 10.1016/j.ejca.2008.09.008